# COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

> **NCT05054218** · — · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 336 (actual)

## Conditions studied

- Covid19
- SARS-CoV2 Infection

## Interventions

- **BIOLOGICAL:** mRNA-1273

## Key facts

- **NCT ID:** NCT05054218
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-10
- **Primary completion:** 2022-07-16
- **Final completion:** 2022-08-29
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2023-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054218, "COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05054218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*